Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry

[1]  M. Kappelman,et al.  Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry , 2020, Inflammatory bowel diseases.

[2]  F. Underwood,et al.  Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.

[3]  S. Feldman,et al.  Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study , 2020, Journal of Allergy and Clinical Immunology.

[4]  K. Hajifathalian,et al.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease , 2020, Gastroenterology.

[5]  Siddharth Singh,et al.  AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. , 2019, Gastroenterology.

[6]  F. Carrat,et al.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease , 2017, JAMA.

[7]  Y. Degboé,et al.  No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis , 2017, RMD Open.

[8]  Zachary A. Capshaw,et al.  Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology , 2015, Emerging Themes in Epidemiology.

[9]  S. Travis,et al.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study , 2013, Gut.